A Medical Device Daily

Quick-Med Technologies (Gainesville, Florida) has entered into a joint development agreement with Foster (Putnam, Connecticut) to collaborate in applying Quick-Med's Nimbus technology to thermoplastics for catheters and other medical product applications.

Catheter-associated urinary tract infection is the most common nosocomial (hospital) infection. Each year, urinary catheters are inserted in more than five million patients in U.S. acute-care hospitals and extended-care facilities and more than one million of those patients acquire a catheter-associated urinary tract infection. When infection occurs, the potential medical and economic consequences can be tremendous, including increased mortality and significant additional healthcare costs.

"We are excited to team with Foster to incorporate our Nimbus technology in catheters," said J. Ladd Greeno, CEO of Quick-Med. "This collaboration will leverage Nimbus technology to a next generation of antimicrobial catheters to address growing infection concerns."

"Our partnership with Quick-Med will enable us to bring innovative, next-generation antimicrobial technology to meet the needs of both existing and potential customers," said Dan Lazas, Foster's VP, marketing & sales. "Nimbus technology will continue Foster's tradition of industry firsts by bringing much needed, uniquely effective and affordable, innovative antimicrobial protection to thermoplastic applications for the medical devices market."

What makes Nimbus different from other antimicrobial technology are its permanent bond and its ability to be effective even in the presence of large amounts of serum and body fluids. The active agent is permanently bonded to the substrate, keeping the biocide from depletion, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. Being bound to the substrate keeps the antimicrobial at full strength; test results show that even in 90% serum, Nimbus continues to kill microbes outperforming other antimicrobials.

When the development is complete and FDA clearance received, management said Nimbus will bring safe, highly effective, and extraordinarily affordable antimicrobial protection to the $12 billion global catheter market which is projected to continue rapid growth for the next several years primarily due to the aging population.

In other agreements/contracts news:

• iMedica (Dallas) reported a technology partnership with Imagetek (Grimes, Iowa) to strengthen the capture of paper-based documents and ease the transition to the paperless physician practice.

The companies have created a solution that provides clinicians with easy and reliable access to patient records, including legacy paper documents, through the Inofile interface. Hosted within the Fujitsu fi-6010N iScanner, Inofile's touch-and-go feature allows clinicians to automatically scan and store documents in the correct location within iMedica's Patient Relationship Manager, a single-application electronic medical record and practice management solution.

• SumTotal Systems (Mountain View, California) reported a partnership with Integrated HR Solutions (IHRS; Chicago) to integrate its healthcare-specific job and competency library into its Healthcare Solution Set for the Talent Development Suite. The Healthcare Solution Set for SumTotal Talent Development Suite is uniquely designed to help hospitals not only address the ever-present regulatory requirements, but also address the workforce issues they face in today's competitive marketplace through content, streamlined workflows, and integrated functionality.

• Aspyra (Calabasas, California) has entered into a non-exclusive letter of agreement with South Plains Biomedical Services (SPBS; Lubbock, Texas), allowing SPBS to represent and resell Aspyra's laboratory and radiology information systems and picture archive communications systems to new and existing SPBS customers. The 12-month letter of agreement became effective February 3, 2009.

• FluGen (Madison, Wisconsin) reported that it has secured exclusive rights to a patent-protected vaccine-delivery technology being commercialized by Ratio (Madison, Wisconsin). Terms of the license agreement were not disclosed.

The disposable micro-device, roughly the size of a poker chip, painlessly delivers seasonal and pandemic influenza vaccines. At the press of a button, a miniature fluidic pump distributes the vaccine to a set of microneedles. These microneedles deliver the vaccine intradermally, or into the skin, but not through it and into the muscle, like the traditional needle and syringe do.

FluGen this year will begin pre-clinical testing of the micro-device with the company's cell-based trivalent influenza vaccines. The company anticipates submitting an investigational new drug application for its vaccine-loaded micro-device to the FDA during the second half of 2010.

No Comments